Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab with or without exclusive enteral nutrition for moderate to severe Crohn's disease with small bowel stenosis
ChiCTR2300075237Phase 4Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ustekinumab in Crohn's disease (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Response of stenosis remission at week 24. Started Jan 2023; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2300075237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075237.